The problem: The chronic pain condition Knee osteoarthritis (OA) affects over 250 million people globally, creating significant social and healthcare challenges, with untreated pain being the #1 patient complaint. In the absence of effective long-term injectable treatments, millions of patients rely on damaging oral medications.
Capsaicin, offers long-lasting, selective pain relief for chronic pain via molecular ablation of pain-sensing nerves only. Despite FDA approval and proven safety and efficacy, its adoption is limited by intense burning pain post-administration, requiring over 1.5 hours of clinic management and making it intolerable for many patients. This has restricted the use of an otherwise highly effective treatment for chronic pain.
Our solution: RM-010 was specifically developed to address the burning pain associated with Capsaicin. Relevium Medical has engineered an innovative drug delivery system that gradually releases Capsaicin into the knee joint, carefully maintaining concentrations below the threshold that triggers burning pain while sustaining levels high enough to achieve full nerve ablation. This breakthrough offers patients a highly tolerable, effective, and safe treatment, delivering long-lasting pain relief with a significantly improved experience. RM-010 is designed for seamless integration into clinical workflows, allowing physicians to administer the therapy in 5 minutes. It provides a practical, patient-friendly solution for effectively managing knee osteoarthritis pain, setting a new standard in treatment care.
Who are are: Relevium Medical, headquartered in Galway, Ireland, is a pioneering pharmaceutical company driven by a passionate team of chemists, neuroscientists, pharmacists, and industry experts. United by a shared mission, the team is dedicated to developing novel solutions to improve the lives of people living with chronic pain.
Interested in hearing more: Get in contact at info@Relevium-Medical.com